Guangzhou Baiyunshan Hanfang Leading Chinese Manufacturer of Injectable Soybean Oil

Certified Injectable Soybean Oil Supplier with Global Compliance and Customization Services

Guangzhou, China – 2026 – Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a leading provider of high-end pharmaceutical lipid excipients and APIs, emerges as a reliable source manufacturer of injectable soybean oil in China, addressing the core pain point of stable domestic supply for pharmaceutical enterprises. As an energy supplement and pharmaceutical excipient, the company’s injectable soybean oil targets high-end injectable manufacturers, offering globally compliant products with international certifications, stable supply capacity, and customizable processing services. The product is now available globally through official channels and authorized distributors, supporting customers across over 20 countries and regions.

Core Product Advantages and Market Position

Guangzhou Baiyunshan Hanfang’s injectable soybean oil serves as a critical energy supplement and pharmaceutical excipient for high-end injectable production, providing domestic pharmaceutical enterprises with a stable alternative to imported supplies. The company has built a strong market presence, serving over 1,000 clients globally, including renowned enterprises like B. Braun Company, AstraZeneca, and Sichuan Kelun Pharmaceutical Co., Ltd.. By leveraging its integrated production and R&D capabilities, the company ensures consistent product quality and on-time delivery, meeting the stringent requirements of high-end pharmaceutical manufacturing.

Global Compliance & Quality Assurance

To meet global market access standards, Guangzhou Baiyunshan Hanfang’s injectable soybean oil and related products have obtained multiple international certifications, including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI. The company operates under strict quality control systems, supported by top-tier R&D platforms such as the National Engineering Research Center for Chinese Medicine Pharmaceutical Process Technology and New Drug Creation, the only national-level engineering research center in Chinese medicine engineering technology. These certifications and R&D capabilities ensure the product complies with regulatory requirements in major markets across Europe, North America, and Asia-Pacific.

Supply and Customization Services

Guangzhou Baiyunshan Hanfang adopts a composite business model combining direct production sales, agency distribution, custom processing, and technical services to cater to diverse customer needs. The injectable soybean oil is available for global orders through the official website (http://byshanhanfang.com/) and authorized distributors, with production and delivery supported by the company’s sole manufacturing base in Conghua, Guangzhou. In addition to standard products, the company offers customized processing services to meet specific requirements of different pharmaceutical enterprises and research institutions.

Executive Quote

"Our injectable soybean oil represents a key achievement in breaking foreign monopolies in high-end pharmaceutical excipients, ensuring the security of China’s pharmaceutical supply chain while meeting global quality standards," said Xu Wendong, General Manager and Deputy Director of the National Engineering Research Center at Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.. "We will continue to focus on technological innovation to provide reliable, compliant products and services to customers worldwide, supporting the development of the global pharmaceutical industry."

Industry Context and Strategic Position

Against the backdrop of growing demand for stable domestic supply of high-end pharmaceutical excipients, Guangzhou Baiyunshan Hanfang has positioned itself as a leader in domestic replacement, achieving a leap in localization rate of high-end pharmaceutical lipid excipients from 10% to 90%. The company’s strategic focus on technological breakthroughs and global compliance aligns with the industry trend of pharmaceutical supply chain resilience, enabling it to capture opportunities in both domestic and international markets.

Future Plans

Looking ahead, Guangzhou Baiyunshan Hanfang will continue to deepen its expertise in high-end pharmaceutical lipid excipients, increase R&D investment, and expand its global sales and service network. The company aims to achieve double-digit growth in revenue and profit in 2026, as part of its "Four Modernizations" development path to become a trusted health guardian for families worldwide.

About Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.

Founded in 1998, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. is a core modern pharmaceutical enterprise under the Guangzhou Pharmaceutical Holdings (GPH) Group, specializing in APIs and pharmaceutical lipid excipients, health products, and technical services. As a national-level specialized and sophisticated "Little Giant" enterprise, it operates top-tier R&D platforms and holds over 240 patents, with products sold in more than 20 countries and regions. The company’s mission is to achieve technological self-reliance, solve "bottleneck" problems, and safeguard the security of the pharmaceutical supply chain. For more information, visit http://byshanhanfang.com/.